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Abstract: Proteins are macro-molecules crucial for cell life, which are made up of amino acids (AAs).
In healthy people, protein synthesis and degradation are well balanced. However, in the presence
of hypercatabolic stimulation (i.e., inflammation), protein breakdown increases as the resulting
AAs are consumed for metabolic proposes. Indeed, AAs are biochemical totipotent molecules
which, when deaminated, can be transformed into energy, lipids, carbohydrates, and/or biochemical
intermediates of fundamental cycles, such as the Krebs’ cycle. The biochemical consequence
of hyper-catabolism is protein disarrangement, clinically evident with signs such as sarcopenia,
hypalbuminemia, anaemia, infection, and altered fluid compartmentation, etc. Hypercatabolic protein
disarrangement (HPD) is often underestimated by clinicians, despite correlating with increased
mortality, hospitalization, and morbidity quite independent of the primary disease. Simple, cheap,
repeatable measurements can be used to identify HPD. Therefore, identification and treatment of
proteins’ metabolic impairment with appropriate measurements and therapy is a clinical strategy that
could improve the prognosis of patients with acute/chronic hypercatabolic inflammatory disease.
Here, we describe the metabolism of protein and AAs in hypercatabolic syndrome, illustrating the
clinical impact of protein disarrangement. We also illustrate simple, cheap, repeatable, and worldwide
available measurements to identify these conditions. Finally, we provide scientific evidence for HPD
nutritional treatment.
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1. Metabolism of Proteins and Amino Acids: Essential Cellular Blocks
Proteins are macronutrients crucial for various cellular activities, as well as body metabolism.
Protein synthesis is primarily controlled by amino acid (AA) availability in stoichiometric quantities
proportional to the number of proteins needed for synthesis and energy requirements needed to
sustain the synthetic process.
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AAs serve many functions within the body. Being the only source of nitrogen for mammals,
AA-derived nitrogen is pivotal for synthetizing precursors (purine and/or pyrimidine) of major energy
molecules (i.e., ATP, ADP, IMP) and/or nucleic acids (i.e., DNA/RNA), and/or to produce compounds
that can regulate major biochemical signaling pathways, such as nitric oxide (NO). Moreover,
deamination of AAs released from skeletal muscle and/or circulating visceral proteins generate
a carbon skeleton rich in oxygen and hydrogen suitable for subsequent biochemical transformation.
This carbon skeleton can be used by the liver to produce glucose through gluconeogenesis and
other macromolecules, such as lipids. The AA-derived carbon skeleton is also relevant in producing
intermediaries fueling the Kreb’s cycle that are thereafter transformed into energy and/or other
metabolic intermediaries (Figure 1). Therefore, AAs can be considered “biochemical totipotent
molecules” able to be converted into energy, carbohydrates, lipids, and biochemical intermediates,
dependent on body metabolic demands [1,2] (Figure 2).
Figure 1. Amino acid-derived intermediates fueling the tri-carboxilic acid cycle (TCA) (Kreb’s
cycle). FFA = free fatty acids. Ala = alanine, Arg = arginine, Asa = aspartic acid, Asn = asparagine,
Cys = cysteine, Gln = glutamine, Glu = glutamic acid, Gly = glycine, His = histidine, Ile = isoleucine,
Leu = Leucine, Lys = lysine, Met = methionine, Phe = phenylalanine, Pro = proline, Ser = serine,
Thr = threonine, Trp = tryptophan, Tyr = tyrosine, Val = valine.
Figure 2. Amino acids (AAs) as biochemical totipotent molecules.
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From a nutritional point of view, AAs are categorized as either “non-essential” (NEAAs) or
“essential” (EAAs). NEAAs are synthetized within the body from carbohydrates and lipids deriving
nitrogen from other AAs. EAAs, however, cannot be synthesized and need to be adequately introduced
with the diet, and they are also the most relevant nutritional input for protein synthesis [3]. For instance,
leucine is considered the primary nutritional regulator of muscle protein anabolism [4] due to its
ability to trigger the mammalian target of the rapamycin (mTOR) pathway and inhibit the proteasome
system [4].
Interestingly, under conditions such as injury, surgery, or chronic diseases, there is increased
demand for AAs as a consequence of higher resting energy expenditure [5]. The consumption of EAAs
into the Kreb’s cycle and its competition with the oxidation of glucose or of fatty acids via β oxidation
has been suggested as a strategy to maintain efficient energy production in pathological conditions.
This is due to fat oxidation being less energy efficient than glycolysis and to the entry of AA-derived
pyruvate into the mitochondrial Kreb’s cycle [6].
Indeed, β oxidation, which is mostly cytoplasmic, reduces the ratio of ATP/available O2,
and obliges large amounts of EAAs to be used as intermediates of the Kreb’s cycle. Interestingly,
EAAs are used as substitutes for pyruvate-derived oxaloacetate shortened by the large amounts of
NADH produced out of mitochondria due to β-oxidation [7].
Such a metabolic shift is one of the main alterations leading to an imbalance between
nitrogen request and nitrogen intake observed in patients with chronic altered metabolic conditions
and measured as the nitrogen balance. This ultimately triggers muscle and circulating protein
disarrangement that become clinically evident in several muscle-wasting conditions (e.g., sarcopenia
and cachexia) and/or hypoalbuminemia with or without anemia [8].
2. The Pathogenesis of Protein Disarrangement: The Hypermetabolic Syndrome
The pathophysiology of syndromes characterized by protein disarrangement is multi-factorial
and dishomogeneous. Indeed, both the elderly and patients with chronic diseases (such as infections
and sepsis) show a pattern of circulating mediators with altered ratios between catabolic molecules
(e.g., TNF-α, cortisol, catecholamines, glucagons, cytokines) inducing protein degradation and anabolic
factors (e.g., insulin, insulin-like growth factors, and growth hormone) that stimulate protein synthesis.
Increased catabolic stimuli and the consequent impaired anabolic/catabolic stimulation is a condition
that can be referred to as the “hypercatabolic syndrome” (HS). This severely impacts whole-body
metabolism and causes an imbalance between nutritional input and synthetic/energy needs [9,10].
Muscle contractile proteins and circulating visceral proteins are the major reservoir of AAs within
the body. Indeed, these proteins can be degraded by catabolic stimuli and/or physical exercises [11]
and other AAs can be re-used by cells for de novo protein synthesis. However, a large amount of AAs
are deaminated to produce energy and other metabolic intermediates via the Kreb’s cycle and/or are
released into the blood stream to maintain a ready-to-use pool of AAs [10] (Figure 3). In this context,
the role of skeletal muscle and circulating visceral proteins goes well beyond that of ensuring posture
maintenance and locomotion and transporting molecules or atoms.
The proteins of skeletal muscle and the circulatory system are in continuous turnover. Several
studies indicate that about 250–350 g of proteins per day are metabolized in healthy individuals.
However, this amount increases dramatically under conditions with higher metabolic demand.
For instance, aged muscles have reduced anabolic response to low doses (e.g., less than 10 g) of
EAAs [12]; yet, higher doses (e.g., 10–15 g, with at least 3 g of leucine) are sufficient to induce a protein
anabolic response comparable to that observed in younger adults [12]. Therefore, it is recommended
that older people consume food rich in high-quality proteins with higher proportions of EAAs, such as
lean meat and other leucine-rich foods (e.g., soybeans, peanuts, chickpeas, and lentils) [13].
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Figure 3. The fate of amino acids (AAs) in muscle cell: physiologic (top) and hypercatabolic syndrome
(HS) and/or insulin resistance (IS) (bottom). The increase in catabolic stimuli enhances protein
breakdown and AA release in the blood stream. These AAs are used almost exclusively for energy
production and gluconeogenesis, but not for de novo protein synthesis. This favors the onset and
aggravation of muscle wasting.
Recently, protein intake above the current recommended dietary allowance (RDA; 0.8 g/kg/day)
has been proposed to preserve muscle health in later life [14–17]. It, therefore, appears appropriate to
promote protein intake of 1.0–1.2 g/kg/day, while 1.2–1.5 g/kg/day of protein may be required in
older adults with acute or chronic conditions [16–18]. Finally, older people with severe illnesses or
overt malnutrition may need as much as 2.0 g/kg/day of protein [17].
It is also important to consider that HS induces “insulin resistance” (IR), a condition which reduces
cytoplasmic and mitochondrial cell protein synthesis and impaired cell metabolism. This reinforces
the protein-amino acid disarrangement [10,19].
3. Clinical Impact of Protein Disarrangements
Alterations in protein balance have been associated with muscle wasting in patients aged 65+,
hospitalized for a variety of chronic disease conditions [20]. Furthermore, approximately 30% of
patients with chronic heart failure exhibit reduced serum albumin (<3.5 g/dL) [21]. Notably, these
conditions are related to increased morbidity, hospitalization, and mortality, independent of primary
diseases, and so increases health-related costs and worse prognosis [11,22].
The central role of muscle proteins for the maintenance of whole-body metabolism, especially
in response to stress (e.g., HS following chronic disease conditions) has recently gained support [23].
Indeed, the maintenance of muscle mass and protein metabolism has been suggested as being a
relevant parameter to include in future studies because of its clinical relevance [23].
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Therefore, the concept of dietary protein intake being calculated as a fixed and limited ratio
(<20%) of total calories has also been questioned. Two major points should be considered: (1) nitrogen
needs may significantly increase independent of caloric demand. This is often overlooked in large
populations (i.e., the elderly with or without chronic diseases); and (2) nitrogen should not be calculated
by using total protein nitrogen content, but by considering individual AAs. This is because dietary
proteins are enriched in NEAAs, which are not fundamental to support global metabolism but do
increase urea synthesis, and EAAs, which are crucial for refuelling proteins and global metabolism.
Thus, insufficient intake of EAAs despite increased need may be a mechanism in obese patients with
chronic disease (i.e., heart failure), further worsening protein metabolism [24].
Dietary intake providing adequate protein amount and, consequently, AAs to match organ
demand, preserves the integrity of organs essential for life, as witnessed by peripheral muscle
homeostasis and, ultimately, patient survival. Conversely, insufficient EAA intake induces muscle and
circulating visceral protein degradation to release AAs to cope for this deficit. Thus, sarcopenia/muscle
wasting and hypoalbuminemia become clinically evident.
HS also reduces the appetite, as well as nausea and digestive disorders in patients with chronic
conditions leading to inadequate nutrition and consequent reduced availability of nutrients, including
AAs [25]. Anamnesis would suggest that eating-related disorders can be found in chronic patients and
specific therapeutic strategies can be implemented. Up to 50% of patients with severe chronic disease
show altered protein metabolism, which is often underestimated by clinicians despite influencing cell
life and having relevant clinical implications [25].
The consequences of protein disarrangement in various body organs and/or systems are
illustrated in Figure 4. Altered protein metabolism in patients with chronic diseases, especially
older ones, may increase the risk of developing life-threatening complications (e.g., infection due
to reduced or circulating T cells and secretion of protein Ig or imbalance of the Na+/K+ ratio)
with consequent water retention, respiratory failure, and pulmonary edema. Furthermore, cardiac
dysfunction, ventricular arrhythmias, and renal insufficiency may also occur [25].
Figure 4. Effects of protein disarrangements on various systems and electrolyte balance.
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4. Clinical Steps to Evaluate Protein Disarrangement
We have recently proposed a panel of practical and inexpensive tools for the clinical evaluation
of protein disarrangement [26]. A set of indirect measurements evaluating body composition
(anthropometric parameters), visceral protein composition (serum albumin, pre-albumin, transferrin,
retinol binding protein, nitrogen balance), muscle protein degradation (serum or urinary excretion of
3-metil histidine), and immuno-competence (total lymphocyte count) has been proposed. However,
a rapid, inexpensive, and easy assessment of protein disarrangements at the bedside is still lacking.
As such, the evaluation of anthropometric parameters should be considered [26].
A simple way to evaluate body composition is to measure tricipital skin-fold thickness (TST,
an index of fat mass) and arm muscle area (AMA, an index of lean mass) as described elsewhere [27,28].
Notably, TST and AMA are not modified by extracellular fluids, so they are useful tools even in patients
with fluid retention. Interestingly, the presence of reduced AMA less than 5th percentile by age and
sex, together with hypoalbuminemia, in the absence of liver and/or renal insufficiency, confirms the
presence of muscle sarcopenia and altered protein metabolism. [29]
Whenever protein disarrangement associated with muscle wasting and hypoalbuminemia is
suspected, the following additional evaluations can be considered.
4.1. Circulating Visceral Proteins
The concentration of serum proteins such as albumin, pre-albumin, transferrin, and retinol
binding proteins are influenced by extra-cellular fluid composition.
Albumin concentration can be included in routine clinical blood measurements as it is easy
to measure, non-invasive, and a repeatable marker. Its concentration correlates with worsening
morbidity and mortality independent of the disease index [30]. Albumin half-life in circulation is about
20 days and the fractional replacement rate is 10% per day. In the absence of chronic stress, increased
serum albumin levels appear within 14 days and a serum concentration <3.5 g/dL indicates impaired
protein metabolism associated with muscle wasting [30]. Concentrations lower than 3.2 g/dL suggest
more pronounced protein metabolism disarrangement. Notably, severe nephrosis, protein-losing
enteropathy, or severe liver insufficiency reduce serum albumin concentrations. Consequently, these
conditions should be excluded when albumin is used as an index of protein status.
Pre-albumin responds quickly to short-term (24–36 h) energy restriction and re-feeding. Repeated
measurements of pre-albumin levels over a week could be a useful measure of both protein depletion
and repletion. This is particularly useful to monitor treatment [30].
Transferrin correlates with mortality and is also influenced by iron metabolism. It has a half-life
of about eight days and can, therefore, be used to monitor the effects of specific intervention.
Retinol-binding protein has a turnover of 12 h. Consequently, it is a measure of rapid protein
metabolism modification.
4.2. Nitrogen Balance
Nitrogen balance (NB) is an indirect measure of dynamic processes of endogenous protein
synthesis (anabolism) and demolition (catabolism). NB is expressed as: NB g/day = NI − NV + 2 g.
This formula includes nitrogen intake/supply in g/day (NI) and urinary nitrogen excretion (NV)
in g/day + 20% NV for non-urea N excretion. Two grams correspond to the nitrogen lost in feces
and sweat.
NB is in equilibrium if its balance equals ± 1 g/day. NB > 1 g/day indicates prevalent protein
synthesis. NB < 1 g/day suggests ongoing protein degradation with AAs used for general metabolic
purpose instead of protein synthesis. Therefore, NB < 1 g/day represents an index of proteins
disarrangement [8,26]. Notably, NB depends on urea excretion that is influenced by the daily amount
of NEAAs that are routed to urea excretion. To obtain reliable information, this parameter should be
monitored frequently.
Nutrients 2018, 10, 391 7 of 11
4.3. 3-Methylistidine
Methylation of histidine is a marker of protein degradation derived from contractile actin and
myosin. A simple and rapid method to estimate the fractional catabolic rate of myofibrillar protein is
the evaluation of 3-methylhistidine: creatinine excretion in the urine. The presence of 3-MeH shows
the presence of proteolysis over the immediate period-hours [8,31,32].
4.4. Blood Lymphocyte Count
The loss of circulating cell-mediated immune competence is present in patients with advanced
heart failure with sarcopenia and metabolism disarrangements. Indeed, the lymphocyte count could
be considered an indirect index of cell proliferation, protein synthesis, and energy availability and can
be used to confirm protein and global metabolic impairment [33].
5. Possible Therapeutic Interventions
Protein intake and AA availability are key to maintaining protein synthesis in living organisms.
Healthy individuals absorb AAs from the diet after protein digestion by pancreatic enzymes. However,
the pancreas uses large amounts of AAs and energy to produce digestive enzymes [10]. The efficiency
of pancreatic and mesenteric circulation may be progressively reduced in HS and/or in chronic
diseases with water retention [34]. In addition, gut microbiota alterations and impaired intestinal
function, including altered nutrient digestion and absorption, have been reported in patients with
chronic disease [34]. These conditions lead to impaired AA digestion and absorption and, consequently,
to reduced AA plasma levels that may become insufficient to maintaining protein synthesis and energy
demand in HS patients [10]. In contrast, individual AAs derived from nutritional supplements are
immediately available after absorption and transit into the bloodstream to be delivered to cells [35].
EAAs stimulate protein synthesis in both young and the elderly [36]. However, it has recently
been shown that specific diets containing blends of individual EAAs in stoichiometric ratios are crucial
for providing AAs for various metabolic needs, such as protein synthesis, mitochondrial biogenesis,
and other important metabolic pathways crucial for cell life [6,37,38]. Indeed, specific EAA mixtures
control protein synthesis in myocytes by activating AMP-activated protein kinase (AMPK) and mTOR,
which regulate energy production/use, protein synthesis, cell proliferation, mitochondrial biogenesis,
and anti-apoptotic process [39].
Clinical and experimental data suggest that oral supplements with specific individual
EAA mixtures ensuring metabolic energy supply, administered traditionally, counteract protein
disarrangement and cellular energy impairment without influencing renal function [40–43]. The clinical
consequences of this is that the percentage of nitrogen and calories provided by diet should be
calculated separately according to metabolic needs. Moreover, the amount of EAAs should be provided
as a function of their intrinsic capacities to maintain proteins and body metabolism. In addition,
individual AAs should be provided so they are not rapidly absorbed, thus increasing their blood
viability [44].
Taken together, these observations could explain why previous studies were unable to show any
effects of simple total protein dietary supplementation on protein and energy metabolism in patients
with chronic diseases [45]. Such findings support the indication that the elderly need increased EAA
to stimulate muscle protein synthesis. This also introduces the concept of evaluating protein AA
composition (protein quality) [46]. A modification of the Dietary Guidelines of Americans (DG of A),
which provides nutrient advice to avoid/reduce age-related nutritional problems, has been proposed
as follows: (1) protein (and more importantly specific AAs) should be a part of the adult/aged
people diet; (2) protein (and more importantly specific AAs) needs for adult/aged people should
be proportional to body weight and/or clinical condition and not as a percentage of total energy
intake; (3) most adult/aged people benefit from protein intake above the minimum recommended
Nutrients 2018, 10, 391 8 of 11
daily allowance. Indeed, to maintain healthy muscles and bones, at least 30 g of high-quality protein
(and more importantly specific EAAs) should be ingested at more than one meal.
The effect of dietary administration of different EAAs blends has been actively investigated in
the recent years [42–44]. Existing findings on the molecular pathways elicited by proteins and AA
metabolism in chronic disease conditions could allow the development of therapeutic strategies to
contrast metabolic impairment, especially in the elderly.
6. Conclusions
The evaluation of protein disarrangement deserves greater attention to manage chronic diseases,
especially in old age (see Box 1). Readily available and inexpensive anthropometric and blood
parameters, such as TST, AMA, and albuminemia, can be obtained routinely at the bedside.
Additional research could unveil the causes of these conditions and monitor the outcome of specific
therapeutic interventions.
Clinicians should consider protein homeostasis as essential to maintaining metabolic competence
in patients with chronic diseases. This is fundamental for any further therapeutic approaches.
The identification and treatment of protein metabolic impairment with appropriate therapies may be
at least as important as any other evaluation and therapeutic strategy implemented in improving the
prognosis of chronically ill patients.
Box 1. Main Messages from the text.
• Proteins are building blocks for living organisms consisting of amino acids (AAs).
• AAs are totipotent biochemical molecules essential for cellular activity.
• Pathological conditions increase protein/AA demand.
• Hypercatabolic syndromes, due to increased inflammation and catabolic hormones, cause
significant changes in body metabolism and lead to an imbalance between nutritional input and
synthetic/energy needs.
• Both circulating (i.e., albumin) and muscle proteins are a reservoir of AAs (above all, essential AAs) within
the body.
• Altered protein metabolism in patients (especially those with chronic diseases and/or older), can increase
the risk of developing life-threatening complications (e.g., infection, cardiac and/or renal dysfunction).
• The pathophysiology of conditions characterized by protein disarrangements (i.e., muscle wasting and/or
hypoalbuminemia) need to be fully clarified to develop adequate therapeutic (nutritional) strategies.
• Clinicians need to consider protein metabolism as a critical aspect for the management of patients with
chronic diseases.
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